{
    "clinical_study": {
        "@rank": "35180", 
        "arm_group": [
            {
                "arm_group_label": "Flutiform 250/10 micrograms", 
                "arm_group_type": "Experimental", 
                "description": "Flutiform 250/10 \u00b5g (2 puffs twice daily)"
            }, 
            {
                "arm_group_label": "Flutiform 125/5 micrograms", 
                "arm_group_type": "Experimental", 
                "description": "Flutiform 125/5 \u00b5g (2 puffs twice daily)"
            }, 
            {
                "arm_group_label": "Formoterol 12 micrograms", 
                "arm_group_type": "Active Comparator", 
                "description": "Formoterol 12 \u00b5g 1 puff twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "Efficacy of Fluticasone/Formoterol in COPD Treatment. The Effect study."
        }, 
        "brief_title": "A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a multi-centre, randomised, double-blind, active-controlled, parallel-group\n      study, in male and female subjects who will be assigned into 1 of 3 treatment groups based\n      on 1:1:1 ratio.  Following a 2 week run-in phase all subjects will receive treatment for 1\n      year (52 weeks) followed by a final follow up 2 weeks after their last visit, during this\n      time subjects will be required to attend 10 clinic visits while the final follow up can be\n      completed by telephone.  Throughout the study subjects will be assessed on a mixture of\n      symptom based measurements as well as lung function tests to monitor their progress in the\n      study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          1. Male or Female subjects aged \u2265 40 years at screening visit:\n\n               1. Female subjects of child bearing potential (less than 1 year post-menopausal)\n                  must have a negative urine pregnancy test prior to first dose of study\n                  medication, be non-lactating, and willing to use adequate and highly effective\n                  methods of birth control throughout the study such as sterilisation, implants,\n                  injectables, combined oral contraceptives, some intra-uterine devices, sexual\n                  abstinence or vasectomised partner.\n\n               2. Male subjects with a partner of child bearing potential must be willing to use\n                  adequate and highly effective methods of birth control throughout the study\n\n          2. Smoking history of \u226510 packs per year.\n\n          3. Diagnosis of COPD\n\n          4. History of \u2265 moderate or severe COPD exacerbations in previous year.\n\n          5. Willing and able to replace current COPD therapy with study medication.\n\n          6. Able to demonstrate correct use of a pMDI without a spacer.\n\n          7. Willing and able to attend all study visits and complete study assessments.\n\n          8. Able to provide signed informed consent.\n\n        Exclusion:\n\n          1. Ongoing moderate or severe exacerbation of COPD (see section 10)\n\n          2. Current diagnosis of asthma\n\n          3. Documented evidence of \u03b11-antitrypsin deficiency as the underlying cause of COPD\n\n          4. Other active respiratory disease such as active tuberculosis, lung cancer,\n             bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung\n             disease, cystic fibrosis, bronchiolitis obliterans\n\n          5. Previous lung resection\n\n          6. Use of long-term oxygen therapy (LTOT) at least 12 hours daily or mechanical\n             ventilation\n\n          7. Chest X-ray or CT scan that reveals evidence of clinically significant abnormalities\n             reflective of active disease not believed to be due to COPD\n\n          8. Evidence of uncontrolled cardiovascular disease\n\n          9. Evidence of clinically significant renal, hepatic, gastrointestinal, or  psychiatric\n             disease\n\n         10. Current malignancy or a previous history of cancer which has been in remission for <\n             5 years (basal cell or squamous cell carcinoma of the skin which has been resected is\n             not excluded)\n\n         11. Clinically significant sleep apnoea requiring use of continuous positive airway\n             pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV) device\n\n         12. Participation in the acute phase of a pulmonary rehabilitation programme within 4\n             weeks prior to screening or during the study\n\n         13. Known or suspected history of drug or alcohol abuse in the last 2 years\n\n         14. Requiring treatment with any of the prohibited concomitant medications\n\n         15. Known or suspected hypersensitivity or contraindication to any of the study drugs or\n             excipients\n\n         16. Received an investigational drug within 30 days of the screening visit (12 weeks if\n             an oral or injectable steroid)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "1530", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946620", 
            "org_study_id": "FLT3509", 
            "secondary_id": "2012-004162-17"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Flutiform 250/10 micrograms", 
                    "Flutiform 125/5 micrograms"
                ], 
                "intervention_name": "Flutiform", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Formoterol 12 micrograms", 
                "intervention_name": "Formoterol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Formoterol", 
                "Fluticasone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic Obstructive Pulmonary Disease", 
            "Exacerbations", 
            "FEV1 \u2264 50%"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Riga", 
                    "country": "Latvia"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Latvia"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-blind, Double Dummy, Parallel Group Study Comparing Fluticasone Propionate / Formoterol Fumarate (Flutiform\u00ae) 250/10 \u00b5g (2 Puffs BID) and Flutiform\u00ae 125/5 \u00b5g (2 Puffs BID) Versus Formoterol Fumarate Dihydrate (Atimos\u00ae) 12 \u00b5g (1 Puff BID) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).", 
        "overall_contact": {
            "email": "info@contact-clinical-trials.com", 
            "last_name": "Margaret C Wilson"
        }, 
        "overall_contact_backup": {
            "email": "info@contact-clinical-trials.com", 
            "last_name": "Jill Kiteley"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Latvia: State Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To show superiority in the efficacy of flutiform 250/10 \u00b5g (2 puffs BID) compared with formoterol 12 \u00b5g (1 puff BID) based on the annual rate of moderate and severe COPD exacerbations", 
            "measure": "Annual rate of moderate and severe COPD exacerbations", 
            "safety_issue": "No", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946620"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To show superiority in the efficacy of flutiform 125/5 \u00b5g (2 puffs BID) compared with formoterol 12 \u00b5g (1 puff BID) based on the annual rate of moderate and severe COPD exacerbations. (Different dose to Primary Outcome)", 
                "measure": "Annual rate of moderate and severe COPD exacerbations", 
                "safety_issue": "No", 
                "time_frame": "52 Weeks"
            }, 
            {
                "description": "To compare flutiform (at each dose) with formoterol 12 \u00b5g (1 puff BID) for the secondary efficacy, and safety endpoints.", 
                "measure": "Efficacy confirmed by lack of exacerbations, lung function and safety by collection of adverse events in all patients throughout the study.", 
                "safety_issue": "No", 
                "time_frame": "52 Weeks"
            }
        ], 
        "source": "Mundipharma Research Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma Research Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}